Valuation
TLXTelix Pharmaceuticals Limited
StockNasdaqAustraliaHealth careEU retail investors: available
+2.2% today · −2.5% over a year
No score: too little data.
Quality: among the weakest. No dividend.
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | TLX | Sector median | vs median |
|---|---|---|---|
| P/E | — | 25.5 · n=26 | — |
| P/B | — | 3.6 · n=45 | — |
| P/S | — | 4.6 · n=40 | — |
| EV/EBIT | — | 22.5 · n=28 | — |
| Free-cash-flow yield | — | 3.7% · n=40 | — |
| Dividend yield | 0.00% | 0.20% · n=99 | 100% below |
| Return on equity | −1.9% | 5.2% · n=56 | 136% below |
| Return on invested capital | 6.3% | 6.5% · n=47 | near the median |
| Gross margin | 53.1% | 70.2% · n=39 | 24% below |
| Net debt / EBITDA | 5.13 | 2.08 · n=25 | 147% above |
Sector peers
The largest companies of the same sector and region.
| NVSNovartis AG | 22.2 | 6.7 | 18.6 | 5.7% | 2.4% | 10/10 |
|---|---|---|---|---|---|---|
| NOVNNovartis AG | 22.2 | 6.7 | 18.6 | 5.7% | 2.8% | 10/10 |
| AZNAstraZeneca plc | 28.3 | 5.9 | 22.8 | 4.1% | 1.7% | 6/10 |
| AZNAstraZeneca PLC | 28.3 | 5.9 | 22.8 | 4.1% | 1.2% | 6/10 |
| NVONovo Nordisk A/S | 11.7 | 6.2 | 10.2 | 4.9% | 4.6% | 7/10 |
| SNYSanofi | 13.2 | 1.4 | 17.9 | 7.0% | 4.5% | 7/10 |
| SANSanofi SA | 13.1 | 1.4 | 17.8 | 7.1% | 4.9% | 9/10 |
| GSKGSK plc | 14.3 | 5.0 | 11.6 | 7.8% | 3.6% | 10/10 |
| TEVATeva Pharmaceutical Industries Limited | 98.3 | 6.2 | 43.5 | 2.5% | 0.0% | 6/10 |
| ALCAlcon | 37.3 | 1.7 | 29.2 | 4.7% | 0.4% | 4/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 31 Dec 2025 · filed 20 Mar 2026
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.